<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334489</url>
  </required_header>
  <id_info>
    <org_study_id>PECEP_LASER Trial</org_study_id>
    <nct_id>NCT01334489</nct_id>
  </id_info>
  <brief_title>The Trial of Pessary After Laser for TTTS</brief_title>
  <acronym>PECEPLASER</acronym>
  <official_title>Arabin Cervical Pessary for Prevention of Preterm Birth in Cases of Twin-to-twin Transfusion Syndrome Treated by Fetoscopic Laser Coagulation: The PECEP Laser Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternal-Infantil Vall d´Hebron Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bürgerhospital Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placing a cervical pessary in severe twin-to-twin transfusion syndrome (TTTS) cases treated&#xD;
      by fetoscopic laser coagulation (FLC) decreases the spontaneous preterm birth rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monochorionic (MC) twin pregnancies present with a high rate of fetal complications, most of&#xD;
      them associated with the placental vascular anastomoses. Fetoscopic laser coagulation (FLC)&#xD;
      is a surgical technique that allows minimally invasive access into the uterus and has emerged&#xD;
      as a useful tool in the management of the most common and severe of these complications, twin&#xD;
      to twin transfusion syndrome (TTTS). Even though, preterm birth remains a common cause of&#xD;
      adverse outcome because TTTS is associated with a 29% risk of delivering before 28 weeks.&#xD;
&#xD;
      A short cervical length (CL), defined as a CL ≤ 25 mm, detected by transvaginal ultrasound is&#xD;
      an independent risk factor for preterm birth in twin pregnancies but no effective treatment&#xD;
      has been described to prevent it.&#xD;
&#xD;
      Although is usually accepted that in twin pregnancies cerclage may increase the risk of&#xD;
      preterm birth, Salomon and co-workers, found that in cases of TTTS with a CL below the 5th&#xD;
      percentile (15 mm) at the time of surgery, performing an emergency cerclage prolonged the&#xD;
      pregnancy and allow for better outcome, But still preterm birth after FLC remains a big&#xD;
      challenge, so new methods to prevent it must be investigated.&#xD;
&#xD;
      Previous studies in singletons and twins have shown that the use of cervical pessary&#xD;
      significantly reduces the frequency of birth before 32 weeks and prolongs pregnancy. The&#xD;
      advantage of using cervical pessary is that it is less invasive than cerclage and can be&#xD;
      removed easily. That's the reason why pessaries could be considered an alternative, non&#xD;
      invasive option to prevent preterm birth in cases of twin to twin transfusion syndrome (TTTS)&#xD;
      treated by laser surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis unfavorable to continue the study&#xD;
  </why_stopped>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery before 32 weeks</measure>
    <time_frame>Within the first 15 days after delivery</time_frame>
    <description>Rate of delivery before 32 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>Within the first 15 days after delivery</time_frame>
    <description>Median weight (g) of the newborns at birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal or neonatal death</measure>
    <time_frame>Within the first 15 days after the death</time_frame>
    <description>Rate of intrauterine demise or neonatal death during the first 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>30 days after the discharge from the hospital</time_frame>
    <description>Rate of major adverse neonatal outcomes before discharge from the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant maternal adverse events</measure>
    <time_frame>Within 15 days after discharge from the hospital</time_frame>
    <description>Rate of heavy bleeding (bleeding that requires a medical intervention), cervical tear (cervical rupture due to the pessary placement), and/or uterine rupture (rupture of the uterus due to contractions or surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical or psychological intolerance to pessary</measure>
    <time_frame>Within 15 days after discharge from hospital</time_frame>
    <description>Discomfort or pain due to the pessary that makes daily life uncomfortable (number of cases).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth before 37 weeks</measure>
    <time_frame>Within 15 days after delivery</time_frame>
    <description>Rate of delivery before 36+6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rupture of membranes before 32 weeks</measure>
    <time_frame>Within 15 days after delivery</time_frame>
    <description>Rupture of amniotic membranes before 31+6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation for threatened preterm labour before 32 weeks</measure>
    <time_frame>Within 15 days after delivery</time_frame>
    <description>Requirement of hospitalisation due to preterm contractions that need medical treatment to try to stop them before 31+6 weeks (rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to birth</measure>
    <time_frame>Within 15 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth before 34 weeks</measure>
    <time_frame>Within 15 days after delivery</time_frame>
    <description>rate of delivery before 33+6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth before 30 weeks</measure>
    <time_frame>Within 15 days after delivery</time_frame>
    <description>rate of delivery before 29+6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth before 28 weeks</measure>
    <time_frame>Within 15 days after delivery</time_frame>
    <description>rate of delivery before 27+6 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Usual management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual management of monochorionic pregnancy without the pessary placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arabin Cervical Pessary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.&#xD;
The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arabin Cervical Pessary</intervention_name>
    <description>The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).&#xD;
It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.</description>
    <arm_group_label>Arabin Cervical Pessary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Monochorionic twin pregnancies with severe TTTS requiring intrauterine surgery&#xD;
&#xD;
          -  Less than 26 weeks&#xD;
&#xD;
          -  Minimal age of 18 years&#xD;
&#xD;
          -  Informed consent signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major fetal abnormalities (requiring surgery or leading to infant death or severe&#xD;
             handicap)&#xD;
&#xD;
          -  Cerclage prior to randomisation&#xD;
&#xD;
          -  Uterine malformation&#xD;
&#xD;
          -  Placenta previa&#xD;
&#xD;
          -  Active vaginal bleeding at the moment of randomization&#xD;
&#xD;
          -  Spontaneous rupture of membranes at the time of randomization&#xD;
&#xD;
          -  Death of both twins after the surgery&#xD;
&#xD;
          -  Monochorionic-monoamniotic twin pregnancy&#xD;
&#xD;
          -  Silicone allergy&#xD;
&#xD;
          -  Current participation in other RCT&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Carreras, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven. Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik - Zentrum für Ultraschalldiagnostik und Pränatalmedizin Bürgerhospital und Clementine Kinderhospital gemeinnützige GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://dr-arabin.de/product-category/products/obstetrics/?lang=en</url>
    <description>Arabin Cervical Pessary</description>
  </link>
  <reference>
    <citation>Carreras E, Arévalo S, Bello-Muñoz JC, Goya M, Rodó C, Sanchez-Duran MA, Peiro JL, Cabero L. Arabin cervical pessary to prevent preterm birth in severe twin-to-twin transfusion syndrome treated by laser surgery. Prenat Diagn. 2012 Dec;32(12):1181-5. doi: 10.1002/pd.3982. Epub 2012 Oct 11.</citation>
    <PMID>23055333</PMID>
  </reference>
  <reference>
    <citation>Goya M, Pratcorona L, Merced C, Rodó C, Valle L, Romero A, Juan M, Rodríguez A, Muñoz B, Santacruz B, Bello-Muñoz JC, Llurba E, Higueras T, Cabero L, Carreras E; Pesario Cervical para Evitar Prematuridad (PECEP) Trial Group. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet. 2012 May 12;379(9828):1800-6. doi: 10.1016/S0140-6736(12)60030-0. Epub 2012 Apr 3. Erratum in: Lancet. 2012 May 12;379(9828):1790.</citation>
    <PMID>22475493</PMID>
  </reference>
  <reference>
    <citation>Goya M, Pratcorona L, Higueras T, Perez-Hoyos S, Carreras E, Cabero L. Sonographic cervical length measurement in pregnant women with a cervical pessary. Ultrasound Obstet Gynecol. 2011 Aug;38(2):205-9. doi: 10.1002/uog.8960. Epub 2011 Jul 18.</citation>
    <PMID>21305638</PMID>
  </reference>
  <reference>
    <citation>Liem S, Schuit E, Hegeman M, Bais J, de Boer K, Bloemenkamp K, Brons J, Duvekot H, Bijvank BN, Franssen M, Gaugler I, de Graaf I, Oudijk M, Papatsonis D, Pernet P, Porath M, Scheepers L, Sikkema M, Sporken J, Visser H, van Wijngaarden W, Woiski M, van Pampus M, Mol BW, Bekedam D. Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label randomised controlled trial. Lancet. 2013 Oct 19;382(9901):1341-9. doi: 10.1016/S0140-6736(13)61408-7. Epub 2013 Aug 5.</citation>
    <PMID>23924878</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monochorionic pregnancy</keyword>
  <keyword>Twin to twin transfusion syndrome</keyword>
  <keyword>Cervical pessary</keyword>
  <keyword>Cervical length</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

